Close Menu

NEW YORK (GenomeWeb) – Early data from an ongoing Phase IIb study suggests that an investigational IL4-targeted toxin from Medicenna Therapeutics may improve survival in recurrent glioblastoma patients, particularly those that have high expression of the IL4 receptor on their tumors.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.